ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET -

FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the continuation of its Virtual Investor Spotlight Series to be held on Thursday, April 14, 2022. Access the full series of events here.

Thursday, April 14, 2022

  • 10:00 AM ET: CEO Spotlight Featuring Aeterna Zentaris (NASDAQ: AEZS) - Register Here
    • Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need.

As part of the virtual event, members of the Aeterna Zentaris management team will provide an overview of its growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). Additionally, the Company will discuss its development progress on an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and Chlamydia trachomatis.

  • 11:30 AM ET: Glioblastoma Multiforme (GBM) Spotlight Featuring CNS Pharmaceuticals (NASDAQ: CNSP) - Register Here
    • CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

As part of the virtual event, members of the CNS Pharmaceuticals management team will be joined by leading Neuro-Oncologist, Samuel A. Goldlust, MD, Pitkin Chair in Neuro-Oncology, Medical Director of the Brain and Spine Institute, John Theurer Cancer Center and an investigator in the Company's global potentially pivotal study, to spotlight GBM, the unmet need and the work CNS Pharmaceuticals is doing to advance it's Berubicin clinical program.

  • 1:00 PM ET: Defense Production Act Spotlight Featuring American Resources Corporation (NASDAQ: AREC) - Register Here
    • American Resources is a next generation and socially responsible supplier of rare earth and critical elements, carbon and advanced carbon materials to the new infrastructure and electrification marketplace.

As part of the virtual event, members from the American Resources management team will discuss the recent charge to the Defense Department from President Biden to consider the metals required to make the batteries used in clean energy technology as essential to national security under the Defense Production Act.

A live video webcast of the Spotlight series events will be available on virtualinvestorco.com. A webcast replay will be made available shortly after the conclusion of the live event and will be accessible for 90 days.

About JTC Team

JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

CONTACT:
Jenene Thomas
JTC Team, LLC
T: +1 (833) 475-8247
jtc@jtcir.com

SOURCE: JTC Team, LLC



View source version on accesswire.com:
https://www.accesswire.com/697228/JTC-Team-Announces-Continuation-of-its-Virtual-Investor-Spotlight-Series-with-NASDAQ-AEZS-NASDAQ-CNSP-and-NASDAQ-AREC

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.